National Institute for Medical Research

Mwanza, Tanzania

National Institute for Medical Research

Mwanza, Tanzania
SEARCH FILTERS
Time filter
Source Type

PARIS--(BUSINESS WIRE)--La Fondation IPSEN(1) contribue au développement et à la diffusion des connaissances scientifiques en encourageant les interactions entre scientifiques et cliniciens. Comme chaque année, le Prix de la Fondation IPSEN consacré aux Régulations Endocrines(2) sera remis aujourd’hui à l’occasion de l’ECE (Congrès Européen d’Endocrinologie) à Lisbonne. Le jury international(3), présidé par le Professeur Iain Robinson (National Institute for Medical Research, Londres, Royaume-Uni), a désigné comme lauréat, Bruce McEwen, pour ses travaux pionniers sur les glucocorticoïdes, le stress et la dégénérescence neuronale. La Fondation IPSEN(1) contribue au développement et à la diffusion des connaissances scientifiques en encourageant les interactions entre scientifiques et cliniciens de différents horizons. Créé en 2002, le prix Régulations Endocrines de la Fondation IPSEN(2) récompense des spécialistes de renom qui ont fait de remarquables découvertes ou apporté des avancées majeures dans le domaine. Le Pr. Bruce McEwen a été sélectionné par un jury international(3) pour ses travaux de recherche pionniers sur les glucocorticoïdes, le stress et la dégénérescence neuronale. Ce prix sera remis lors de l’ECE (Congrès Européen d’Endocrinologie) et sera suivi d’une conférence spéciale de Bruce McEwen. Durant sa présentation, Bruce McEwen discutera le rôle des hormones stéroïdes produites par le cerveau dans la régulation de nombreuses fonctions cérébrales. Ce travail a permis d’élargir la définition de « neuroendocrinologie » en incluant les voies de signalisations hormonales et neuronales dans la communication réciproque entre le cerveau et les tissus périphériques. Le cerveau est l’organe central du stress et de la réponse au stress puisqu’il perçoit et détermine ce qui est réellement menaçant, et module la réponse comportementale et physiologique face à l’élément stressant. Le cerveau adulte et en développement possède une remarquable plasticité structurale et fonctionnelle en réponse au stress. Ceci inclue le remplacement de neurones, le remodelage dendritique et le renouvellement des synapses. Le stress cause un déséquilibre des circuits neuronaux qui modulent les fonctions cognitives, la prise de décisions, l’anxiété et l’humeur. Ce déséquilibre affecte, en retour, les organes périphériques via des processus neuroendocrines, immunitaires, métaboliques ou des voies autonomes. A court-terme, comme pour la vigilance et l’anxiété qui augmente dans un environnement stressant, ces changements peuvent être adaptatifs. Cependant, si le danger passe mais que l’état comportemental et les changements neuronaux persistent, cette mauvaise adaptation doit être traitée, notamment par une combinaison de thérapies pharmacologiques et comportementales, comme dans le cas d’une anxiété chronique ou d’une dépression. De plus, des expériences défavorables au cours de l’enfance produisent des effets de longue durée sur le cerveau et le corps, notamment par des mécanismes épigénétiques. Alors que la prévention est ce qu’il y a de plus efficace, la plasticité cérébrale apporte de l’espoir pour des thérapies tenant compte des interactions entre le cerveau et le corps. Biographie Bruce S. McEwen a obtenu son doctorat en biologie cellulaire en 1964 au sein de la Rockefeller University (New York, Etats-Unis). Il est membre de l’Académie Nationale des Sciences et de Médecine, ainsi que de l’Académie Américaine des Arts et des Sciences. Il a également occupé le poste de président de la Société américaine des Neurosciences (1997-1998). En tant que neuroscientifique et neuroendocrinologiste, McEwen étudie les variations d’expression de gènes dans le cerveau suite à des changements environnementaux, via les hormones stéroïdes circulantes et cérébrales, en relation avec la différenciation sexuelle cérébrale et les actions des hormones sexuelles et du stress sur le cerveau adulte. Son laboratoire a découvert la présence de récepteurs aux hormones surrénaliennes dans l’hippocampe en 1968, ce qui a ouvert la porte à des études portant sur le rôle de ces hormones sur les fonctions cognitives, la régulation de l’humeur et d’autres fonctions cérébrales. Son laboratoire combine une approche moléculaire, anatomique, pharmacologique, physiologique et comportementale et exploite leurs données en clinique. Son travail de recherche se focalise sur les effets du stress sur l’amygdale, le cortex préfrontal et l’hippocampe. Ils investissent également sur les effets des hormones sexuelles et les différences intersexuelles dans ces régions cérébrales sur les fonctions cognitives et la régulation de l’humeur. Il a servi au sein de la « Fondation MacArthur Research Network on Socioeconomic Status and Health », dont la mission était de contribuer à reformuler les concepts et les mesures relatives au stress et les hormones du stress dans le contexte des sociétés humaines. Ceci a abouti au concept de charge et de surcharge allostatique qui décrit l’usure du corps et du cerveau dû au stress chronique et au mode de vie, engendrant ainsi des dérégulations des mécanismes de stress physiologique, normalement protectifs. Il est aussi un membre du conseil national sur le développement de l’enfant qui se consacre à l’intégration des expériences de l’enfance et promeut un développement sain du cerveau. Il est également le co-auteur avec Elizabeth Lasley d’un ouvrage paru en 2002 « The End of Stress as we know it » (la fin du stress tel que nous le connaissons), destiné au grand public, et de « The Hostage Brain » (le cerveau otage), co-écrit en 1994 avec Harold M. Schmeck. (1) La Fondation IPSEN Créée en 1983 sous l'égide de la Fondation de France, la Fondation IPSEN a pour ambition d’initier une réflexion sur les grands enjeux scientifiques des années à venir. Inscrite dans la durée, l'action de la Fondation IPSEN vise à contribuer au développement et à la diffusion des connaissances scientifiques en encourageant les interactions entre scientifiques et cliniciens. La Fondation a développé un important réseau international d'experts scientifiques qu’elle réunit régulièrement dans le cadre de Colloques Médecine et Recherche, consacrés à trois grands thèmes : les neurosciences, l'endocrinologie et le cancer. Par ailleurs, la Fondation IPSEN a initié plusieurs séries de réunions en partenariat avec le Salk Institute for Biological Studies, le Karolinska Institutet, ainsi qu’avec les revues Cell et Science. La Fondation IPSEN a publié plus d’une centaine d’ouvrages et a attribué plus de 250 prix et bourses scientifiques. www.fondation-ipsen.org (2) Prix Régulations Endocriniennes Créé en 2002, ce Prix de la Fondation IPSEN est décerné annuellement à des spécialistes de renom : Wylie VALE (2002), Robert LEFKOWITZ (2003), Pierre CHAMBON (2004), Thomas HÖKFELT (2005), Roger CONE (2006), William CROWLEY (2007), Ronald EVANS (2008), Gilbert VASSART (2009), Shlomo MELMED (2010), Paolo SASSONE-CORSI (2011), Jeffrey M. FRIEDMAN (2012), Bert O’MALLEY (2013), Maria I. NEW (2014), C. Ronald Kahn (2015) et John W. FUNDER (2016). (3) Membres du Jury Iain ROBINSON (National Institute for Medical Research, Londres, Royaume-Uni) Président, Xavier BERTAGNA (Hôpital Cochin, Paris, France), Felipe CASANUEVA (Université de Saint Jacques de Compostelle, Espagne), Michael CONN (Texas Tech University Health Sciences Center, El Paso, États-Unis), Ezio GHIGO (Ospedale Molinette, Turin, Italie), Ilpo HUHTANIEMI (Imperial College Faculty of Medicine, Londres, Royaume-Uni), Gérard KARSENTY (Columbia University Medical Center, New York, États-Unis), Paul KELLY (Faculté de Médecine Necker Enfants Malades, Paris, France), Stafford LIGHTMAN (University of Bristol, Bristol, Royaume-Uni), Günter STALLA (Max Planck Institute of Psychiatry, Münich, Allemagne) Phyllis WISE (University of Illinois-Champaign, Champaign, États-Unis).


PARIS--(BUSINESS WIRE)--The Fondation IPSEN(1) contributes to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians. The Fondation IPSEN Endocrine Regulations Prize(2) will be presented today at the ECE (European Congress of Endocrinology) in Lisbon. An international jury(3) chaired by Professor Iain Robinson (National Institute for Medical Research, London, UK), awarded the prize to Bruce Mc Ewen for his pioneering work on glucocorticoids, stress and neuronal degeneration. The Fondation IPSEN(1) contributes to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians from different backgrounds. Created in 2002, the Endocrine Regulations Prize(2) of the Fondation IPSEN awards renowned specialists who made breakthrough discoveries or significant progress in the field. Pr Bruce McEwen has been awarded by an international jury(3) for his pioneering work on glucocorticoids, stress and neuronal degeneration. The prize will be presented at the ECE (European Congress of Endocrinology), followed by a lecture given by Bruce McEwen. During his talk, Bruce McEwen will discuss about the role of the steroid hormones that are produced in the brain which mediate every aspect of brain function. This has broadened the definition of ‘neuroendocrinology’ to include the reciprocal communication between the brain and the body via hormonal and neural pathways. The brain is the central organ of stress and adaptation to stress because it perceives and determines what is threatening, as well as the behavioural and physiological responses to the stressor. The adult and developing brain possess remarkable structural and functional plasticity in response to stress, including neuronal replacement, dendritic remodelling, and synapse turnover. Stress causes an imbalance of neural circuitry subserving cognition, decision-making, anxiety and mood. This imbalance, in turn, affects systemic physiology via neuroendocrine, autonomic, immune and metabolic mediators. In the short term, as for increased fearful vigilance and anxiety in a threatening environment, these changes may be adaptive. But, if the danger passes and the behavioural state persists along with the changes in neural circuitry, such maladaptation may need intervention with a combination of pharmacological and behavioural therapies, as is the case for chronic anxiety and depression. Moreover, adverse early-life experience, produce lasting effects on brain and body over the life-course via epigenetic mechanisms. While prevention is most important, the plasticity of the brain gives hope for therapies that take into consideration brain–body interactions. Biography Bruce S. McEwen obtained his Ph.D. in Cell Biology in 1964 from The Rockefeller University. He is a member of the US National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. He served as President of the Society for Neuroscience in 1997-98. As a neuroscientist and neuroendocrinologist, McEwen studies environmentally-regulated, variable gene expression in brain, mediated by circulating steroid hormones and endogenous neurotransmitters in relation to brain sexual differentiation and the actions of sex and stress hormones on the adult brain. His laboratory discovered adrenal steroid receptors in the hippocampus in 1968 that was the gateway for discovering effects of circulating hormones on cognitive function, mood regulation and other CNS functions. His laboratory combines molecular, anatomical, pharmacological, physiological and behavioral methodologies and relates their findings to human clinical information. His current research focuses on stress effects on amygdala and prefrontal cortex, as well as hippocampus, and his laboratory also investigates sex hormone effects and sex differences in these brain regions involved in cognitive function and mood regulation. He served on the MacArthur Foundation Research Network on Socioeconomic Status and Health, in which he has helped to reformulate concepts and measurements related to stress and stress hormones in the context of human societies. This led to the concept of “allostatic load and overload” that describes the wear and tear on the body and brain from chronic stress and related life style behaviors that lead to dysregulation of physiological stress pathways that are normally protective. He is also a member of the National Council on the Developing Child which focuses on biological embedding of early life experiences and promoting healthy brain development. He is the co-author of a book with science writer, Elizabeth Lasley, for a lay audience called “The End of Stress as We Know It”, published in 2002, and “The Hostage Brain” with science writer, the late Harold M. Schmeck, Jr., published in 1994. (1) The Fondation IPSEN Established in 1983 under the aegis of the Fondation de France, the ambition of the Fondation IPSEN is to initiate a reflection about the major scientific issues of the forthcoming years. The long-standing mission of the Fondation IPSEN is to contribute to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians. It has developed an important international network of scientific experts who meet regularly at meetings known as Colloques Médecine et Recherche, dedicated to three main topics: neurosciences, endocrinology and cancer science. Moreover the Fondation IPSEN has started several series of meetings in partnership with the Salk Institute, the Karolinska Institute as well as with the journals Cell and Science. The Fondation IPSEN produced several hundred publications and more than 250 scientists have been awarded prizes and grants. www.fondation-ipsen.org (2) The Endocrine Regulations Prize laureates Created in 2002, this Prize of the Fondation Ipsen has been awarded to following the renowned specialists: Wylie VALE (2002), Robert LEFKOWITZ (2003), Pierre CHAMBON (2004), Thomas HÖKFELT (2005), Roger CONE (2006), William CROWLEY (2007), Ronald EVANS (2008), Gilbert VASSART (2009), Shlomo MELMED (2010), Paolo SASSONE-CORSI (2011), Jeffrey M. FRIEDMAN (2012), Bert O’MALLEY (2013), Maria I. NEW (2014), C. Ronald Kahn (2015) and John W. FUNDER (2016). (3) Members of the jury Iain ROBINSON (National Institute for Medical Research, London, UK), President Xavier BERTAGNA (Hôpital Cochin, Paris, France) Felipe CASANUEVA (University of Santiago de Compostela, Santiago de Compostela, Spain) Michael CONN (Texas Tech University Health Sciences Center, El Paso, USA) Ezio GHIGO (Ospedale Molinette, Turin, Italy) Ilpo HUHTANIEMI (Imperial College Faculty of Medicine, London, UK) Gérard KARSENTY (Columbia University Medical Center, New York, USA) Paul KELLY (Faculté de Médecine Necker Enfants Malades, Paris, France) Stafford LIGHTMAN (University of Bristol, Bristol, UK) Günter STALLA (Max Planck Institute of Psychiatry, München, Germany Phyllis WISE (University of Illinois, Urbana, USA).


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH-2007-2.3.2-4 | Award Amount: 3.94M | Year: 2008

The Partners propose to conduct a cohort study in pregnant women and their newborns to quantify the effects of Pregnancy-Associated Malaria (PAM) and to identify a PAM vaccine candidate. Effects of PAM on the pregnant woman (placental infection and anaemia), the offspring (birth weight reduction), and the infant (increased morbidity and mortality) are well known. Studies underlined the role of P. falciparum variable surface antigens expressed on infected erythrocytes in binding to placenta. A specific immune response against this antigen reduces the effect of PAM during latter pregnancies, making possible to develop a new preventive strategy based on the enhancement of this specific response. This goal will be achieved through cohort studies in 2 endemic areas (West and East Africa), as the mechanisms and the resulting effects may vary with transmission. Biological samples will be collected during pregnancy and infancy to dissect the pathological and immune mechanisms involved, as well as to characterize phenotypically and genetically the infecting parasites, providing a structural basis for anti-PAM vaccine design. The immunopathological effects will be measured in the mothers, their newborns, and the infant, in relation with timing of infection. The ultimate goal is to identify the most immunogenic epitopes of VAR2CSA (the major variable surface antigens of P. falciparum parasites infecting the pregnant women) to be included in such a vaccine. It is anticipated that the product of this project will be directly usable to enter in the pipeline of vaccine development. The 7 Partners of the consortium (5 from 4 EU countries, and 2 from Benin and Tanzania) have a combined history of high class, internationally-recognized research in malaria. All EU teams have huge experience of collaboration with malaria endemic countries institutions and with studies related to malaria in pregnant women, that are also routinely conducted by the 2 African Partners.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP-SICA | Phase: HEALTH-2009-4.3.1-3 | Award Amount: 13.73M | Year: 2010

Worm infections are receiving increased attention due to: the wide geographic overlap in occurrence between worms and HIV, TB and malaria; the large proportion of individuals (minimal estimates around 25%) co-infected with worms and HIV/TB/ malaria; the potential risk of increasing disease burden; the very limited understanding of the impact by worm infections on HIV-, TB- and malaria-specific immune responses and on their clinical outcome; the lack of established intervention guidelines for treatment of worm infections; and the scarce information on the impact by worm infections on vaccination and vaccine-induced immune responses. In order to address these complex and challenging scientific issues, IDEA project will focus its efforts on four primary objectives: a) the worm-induced modulation of the functional and molecular profile of HIV-, TB- and malaria-specific immune responses, b) the impact by worm co-infections on measures of disease activity of PRDs, c) the immunologic markers of worm-, HIV-, TB- and malaria-specific immune responses associated with better control of pathogen replication and disease, and d) the modulation by worm co-infections of vaccine-induced immune responses. To achieve these objectives, IDEA project has developed a global and innovative strategy which includes: a) the alliance between African and European leading scientists in the field of worms, HIV, TB and malaria, b) the multidisciplinary expertise involving immunologists, parasitologists, epidemiologists, clinicians, and experts in vaccines, c) cutting edge immunology and the most innovative technologies to profile immune response, d) the access to large cohort studies bringing a number of centres working on worms and PRDs in Africa together, and e) the access to experimental HIV, TB and malaria vaccine candidates under clinical development in Africa.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP-SICA | Phase: HEALTH.2010.2.3.2-4 | Award Amount: 15.40M | Year: 2011

The AvecNet consortium will develop practical solutions to the current limitations of vector control strategies in Africa using a combination of translationally-aware, state of the art science and end user analysis to ensure successful development and uptake of the new and improved approaches to malaria control and elimination. Our carefully balanced, multidisciplinary team of European and African experts includes vector biologists, engineers, epidemiologists, social scientists and leaders of large supranational consortia. These partners are all prominent members of global vector control research programs having unique specialization in Africa-centric projects. Together we have developed a proposal focused specifically to address the three major research challenges that confront efforts to interrupt mosquito-mediated transmission of malaria in Africa: 1. The need for practical strategies to prolong the efficacy of existing insecticide-based vector control methods, 2.The need to develop new interventions that target all major malaria vectors, that are simultaneously effective, socially acceptable and sustainable, 3. The impact of the major demographic and environmental changes occurring in Africa on malaria epidemiology and control. These research activities are cross-linked by specific tasks to reinforce our commitment to ensure sustainability, engage all stakeholders and strengthen research capacity in Africa. Overall, the project will add significant value to the international research effort in vector control by taking forward the state of the art and translating this into new or improved control tools that will be trialled within the time frame of this project. The studies planned in this collaborative project will provide scalable solutions, giving the solid platform upon which ongoing and future vector control programmes can be built.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP-SICA | Phase: HEALTH-2009-4.3.2-1 | Award Amount: 3.63M | Year: 2010

Objectives: The research aims to improve the delivery of reproductive health (RH) services in Tanzania and Niger by generating new evidence about effective ways to strengthen the provision, uptake, equity and effectiveness of adolescent reproductive health (ARH) programmes. Background: Poor adolescent reproductive health (ARH) continues to be a major cause of morbidity and worsening poverty for the poorest people in sub-Saharan Africa. The effectiveness of ARH programmes implemented within the health and education sectors is seriously hampered by adverse prevailing cultural norms and practices within those sectors and the wider community, and by poor programme integration. Methods: The proposed research will promote equitable reproductive health (RH) service provision and improve its uptake and effectiveness by : (i) conducting a situation analysis of current community and implementer experiences of existing ARH programmes in Tanzania and Niger, identifying priority areas of weakness in RH service provision and opportunities for strengthened service uptake and integration; (ii) addressing identified weaknesses and opportunities by developing an innovative package of interventions in 4 areas: (1) workplace ARH strategy in health units; (2) RH support to teachers in schools; (3) integrated school and community guardian support to pupils; (4) enhanced community referral to health services. We will evaluate the processes and impact of the interventions through a series of rigorous process evaluation studies, which will generate new knowledge, about intervention development, and indicators of intervention processes and effect. The overall impact of the interventions will be evaluated in a population-based cluster randomised trial. Involvement as project partners of the government ministries directly responsible for ARH policy in both Niger and Tanzania, will ensure the policy-relevance of this research, and its continued impact beyond the life of this project.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-09-2015 | Award Amount: 28.14M | Year: 2016

Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the European HIV Vaccine Alliance (EHVA) program will develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. The Specific Objectives of the MVP are to build up: 1.Discovery Platform with the goal of generating novel vaccine candidates inducing potent neutralizing and non-neutralizing antibody responses and T-cell responses, 2. Immune Profiling Platform with the goal of ranking novel and existing (benchmark) vaccine candidates on the basis of the immune profile, 3. Data Management/Integration/Down-Selection Platform, with the goal of providing statistical tools for the analysis and interpretation of complex data and algorithms for the efficient selection of vaccines, and 4. Clinical Trials Platform with the goal of accelerating the clinical development of novel vaccines and the early prediction of vaccine failure. EHVA project has developed a global and innovative strategy which includes: a) the multidisciplinary expertise involving immunologists, virologists, structural biology experts, statisticians and computational scientists and clinicians; b) the most innovative technologies to profile immune response and virus reservoir; c) the access to large cohort studies bringing together top European clinical scientists/centres in the fields of prophylactic and therapeutic vaccines, d) the access to a panel of experimental HIV vaccines under clinical development that will be used as benchmark, and e) the liaison to a number of African leading scientists/programs which will foster the testing of future EHVA vaccines through EDCTP


Grant
Agency: European Commission | Branch: FP7 | Program: CSA-CA | Phase: HEALTH.2011.3.4-3 | Award Amount: 2.29M | Year: 2011

Inequalities and vulnerable groups health, as well as the slow advances to achieve the health- related Millennium Development Goals, are concerns that need to be addressed, notably for low and middle-income countries. While some countries have made advances, these remain unknown to other ones which could still benefit from their experience. Higher collaboration could help but is quite difficult to achieve. The MASCOT project gathers therefore 11 partners from 3 geographical areas (Europe, Latin America & Africa), an advisory board and additional relevant experts to answer this problematic. The work is specifically designed to achieve defined objectives: - to create links between North-South and South-South efforts in addressing maternal and child health and health inequalities (MCH&I) in developing countries - to provide evidence on best practice and policy advice for the development of future public health and health systems interventions. Following a first step of standardisation and quality control procedures, the project will implement mapping activities in individual countries of the 3 regions of interest in order to assess the current situation of MCH inequalities, to identify institutions and research teams performing research in this area, to detect promising projects and research results as well as strategies, programs and policies implemented to tackle MCH inequalities. This will result in recommendations of best practices and policy advice to countries willing to implement actions to improve MCH&I. An important part of the work will also stimulate multi-lateral collaboration and knowledge transfer as a key activity of MASCOT. All along the project, different tools such as meetings, workshops, partnering event, website, and brochures will be used to communicate and promote the exchange between health stakeholders and policy-makers. Ultimately MASCOT should thus allow reducing gaps in health inequalities between and within different regions of the world.


Melanie Lee, PhD, est depuis novembre 2014 directrice scientifique de BTG plc, une entreprise de médecine interventionnelle en maladies vasculaires, oncologie et pneumologie. Après sa carrière universitaire, elle a passé dix ans chez Glaxo/GlaxoWellcome (1988-1998). En 1998, Melanie Lee a rejoint Celltech plc en tant que Directeur exécutif chargé de la Recherche. Celltech plc a ensuite été acquise par UCB, dont Melanie Lee a été nommée Vice-Président exécutif, Recherche et Développement. Après avoir quitté UCB en 2009, elle est devenue directrice générale de Syntaxin Ltd, une biotech basée au Royaume-Uni et, à la suite de la vente de l'entreprise à Ipsen, a fondé en 2014 NightstaRx Ltd, une entreprise soutenue par Syncona. Melanie Lee est diplômée en biologie de l'Université de York et titulaire d'un doctorat du National Institute for Medical Research de Londres. Elle a poursuivi des études post-doctorales en génétique moléculaire, tout d'abord sur les levures à l'Imperial College de Londres puis, à partir de 1985, aux côtés du prix Nobel Sir Paul Nurse, aux  Lincoln's Inn Laboratories de l'Imperial Cancer Research Fund. Melanie Lee a été élevée en 2009 au grade de commandeur dans l'ordre de l'Empire britannique (CBE) pour service rendu à la science médicale. Bernard Charlès est depuis mai 2016 Vice-président Directeur Général de Dassault Systèmes,  leader mondial dans le domaine des logiciels 3D avec plus de 220 000 clients dans 12 secteurs de l'économie. Il était Directeur Général de Dassault Systèmes depuis septembre 1995. Ayant rejoint l'entreprise en 1983, il y crée le département Nouvelles technologies, Recherche et Stratégie et, en 1988, est nommé Directeur Stratégie, Recherche et Développement. Inspirateur des concepts de maquette digitale, gestion de cycle de vie du produit et 3DEXPERIENCE®, Bernard Charlès a contribué à mettre en place une dynamique d'innovation permanente pour asseoir la puissance scientifique de  Dassault Systèmes et inscrire la science dans l'identité de l'entreprise. Bernard Charlès est membre de l'Académie des Technologies (France) et de la National Academy of Engineering (Etats-Unis). Ancien élève de l'Ecole Normale Supérieure de Cachan, il est agrégé et docteur en mécanique, spécialisé dans l'ingénierie de l'automatisation et des sciences informatiques. Sanofi, l'un des leaders mondiaux de la santé, s'engage dans la recherche, le développement et la commercialisation de solutions thérapeutiques centrées sur les besoins des patients. Sanofi est organisé en cinq entités globales : Diabète et Cardiovasculaire, Médecine générale et Marchés émergents, Sanofi Genzyme, Sanofi Pasteur et Santé Grand Public. Sanofi est coté à Paris (EURONEXT: SAN) et à New York (NYSE: SNY).


Sanofi's Board of Directors Proposes Appointment  of Melanie Lee, PhD and Bernard Charlès as New Independent Directors Paris, France - March 2,2017 - At its meeting held on March 2, 2017, the Board of Directors of Sanofi proposed the appointment of Melanie Lee, PhD and Bernard Charlès as new independent Directors during the General Shareholders' meeting of May 10, 2017, as well as the renewal of the term of Fabienne Lecorvaisier. Melanie Lee, PhD, CBE, is Chief Scientific Officer at BTG plc (since November 2014), a company which operates in interventional medicine in vascular disease, oncology and pulmonology.  Following her academic career she spent 10 years at Glaxo/GlaxoWellcome (1988-1998). In 1998, Melanie joined Celltech plc as Executive Director of Research. Celltech plc was subsequently acquired by UCB where she became Executive Vice President, Research and Development. After leaving UCB in 2009 she had a successful tenure as CEO at Syntaxin Ltd, a UK based biotech and following the sale to Ipsen, founded NightstaRx Ltd, a Syncona backed company in 2014. Melanie received an undergraduate degree in Biology from the University of York and then a Ph.D. at National Institute for Medical Research in London. She worked as a molecular genetics postdoc, first at Imperial College London on yeast and then from 1985 with Sir Paul Nurse, a Nobel Prize winner, at the Imperial Cancer Research Fund's Lincoln's Inn Laboratories. Melanie received her CBE for services to medical science in 2009. Bernard Charlès has served since May 2016 as Vice-Chairman and Chief Executive Officer of Dassault Systèmes, a world leader in 3D software with over 220,000 customers in 12 industry sectors. He has been CEO of Dassault Systèmes since September 1995. He joined the company in 1983 and created the New Technology, Research and Strategy division, before being appointed Director for Strategy, Research and Development in 1988. Through his contributions to digital mock-up, product lifecycle management and 3DEXPERIENCE®, Bernard Charlès helped instill a culture of ongoing innovation to further consolidate Dassault Systèmes' scientific capabilities and make science part of the company's identity. Bernard Charlès is a member of the Academy of Technology (France) and of the National Academy of Engineering (United States). He is a graduate of the Ecole Normale Supérieure engineering school in Cachan and has a Ph.D. in mechanical engineering majoring in automation engineering and information science. He also holds an Aggregation in mechanical engineering; this is the most senior teaching qualification achievable in France. "Melanie Lee is a renowned scientific expert with a deep knowledge of the pharmaceutical industry and Bernard Charlès has made Dassault Systèmes an international success. They will bring their strengths to further reinforce the capabilities of the Board and contribute significantly to Sanofi's strategy, both in the area of innovation and to the leveraging of opportunities afforded by digital development," said Serge Weinberg, Chairman of the Board, Sanofi. Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Loading National Institute for Medical Research collaborators
Loading National Institute for Medical Research collaborators